Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Bruton's tyrosine kinase (BTK) inhibitors represent a significant advancement in treating chronic lymphocytic leukemia (CLL).
• FDA-approved BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib offer improved progression-free survival (PFS) over traditional chemoimmunotherapy.

Purpose of the Study:

• To review and compare the efficacy and safety profiles of currently available BTK inhibitors for CLL treatment.
• To provide guidance on selecting the most appropriate BTK inhibitor based on individual patient characteristics and clinical practice.

Main Methods:

• Review of clinical trial data and real-world evidence for ibrutinib, acalabrutinib, and zanubrutinib.
• Analysis of progression-free survival (PFS) benefits and adverse event profiles associated with each agent.

Main Results:

• All three FDA-approved BTK inhibitors demonstrate comparable efficacy in improving PFS for CLL patients.
• Differences in BTK inhibitor selectivity lead to distinct adverse effect profiles, which become more apparent with longer follow-up and real-world data.
• Current data suggest similar efficacy among the agents, but patient-specific factors influence treatment choice.

Conclusions:

• BTK inhibitors have revolutionized CLL management, offering superior PFS compared to chemoimmunotherapy.
• Understanding the nuanced differences in side effect profiles is crucial for optimizing patient care.
• Personalized selection of BTK inhibitors is recommended for effective and safe CLL treatment.